A trial of 40 cognitively normal amyloid-positive individuals will explore the feasibility of using an intranasal insulin delivery device (NCT05006599)
Simplified Insurance and Prior Authorization A significant hurdle to initiating weight loss therapy is insurance navigation, but Klinic simplifies this for you
Y = B max *X/(Kd + X) + NS*X + Background (X: ligand concentration, Y: total binding, B max : Maximum binding, Kd: Equilibrium dissociation constant, NS: slope of the nonlinear regression, Background: measured binding with no added ligand)
By randomizing the order of the interventions (L-carnitine and placebo) and ensuring a 1-week washout period between each treatment, the study controls for potential carryover effects
DM me I'll open the playbook and show you the direction
Fundam Appl Toxicol 7, 54765